Skip to main content

Market Overview

Daewoong Pharmaceutical Injects More Liquidity In Evolus


Evolus Inc (NASDAQ: EOLS) has announced that its strategic partner Daewoong Pharmaceutical Co. Ltd will pay Evolus $25.5 million in cash and eliminate $10.5 million of current and potential future milestone payments.

  • Additionally, Daewoong will convert its debt into Evolus common shares, further reducing $40.5 million in convertible debt.
  • Previously in January, the company eliminated $76.4 million in senior debt from Oxford Finance.
  • Pro-forma cash position reached approximately $57 million and eliminated $127.4 million in debt and milestone payments.
  • "We have resolved all legal matters relating to the International Trade Commission case with all parties and have a heightened focus on driving the growth of Jeuveau in the United States with plans to expand internationally with our European launch of Nuceiva in early 2022.", said David Moatazedi, President and CEO.
  • The company will disclose more details in the fourth quarter financial update scheduled for tomorrow.
  • Price Action: EOLS shares are up 15.4% at $16.56 in market trading hours on the last check Tuesday.

Related Articles (EOLS)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care Financing Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at